85 WELLS AVENUE, NEWTON, MA
Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Annual Report to Security Holders
Other Events
Investor Presentation
News, Material Contracts
Submission of Matters to a Vote of Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Q1
FY 2024
Q3
Q2
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Amended Tender Offer Statement by Issuer